Table 2 Baseline characteristics of patients with sustained viral suppression over 24 months in the Infectious Diseases. Institute research cohort

Variable

CD4 increase < 50 cells/μl

CD4 increase ≥ 50 cells/μl

P value*

CD4 increase < 100 cells/μl

CD4 increase > 100 cells/μl

P value

CD4 increase < 200 cells/μl

CD4 increase > 200 cells/μl

P value

SO-CD4

78 (21%)

302 (79%)

151 (45%)

188 (55%)

166 (54%)

143 (46%)

Age (yrs), [median (IQR)]

38(33–44)

37(33–43)

38(33–45)

37(32–44)

37(32–44)

41(34–45)

≤ 35

30(38%)

126(42%)

0.60

53(35%)

84(45%)

0.14

58(35%)

69(48%)

0.02

Gender

Female

53(68%)

216(71%)

0.54

108(71%)

136(72%)

0.87

120(72%)

107(74%)

0.62

BMI increase [median (IQR)]

0.83 (-0.4–2.0)

1.31 (0–2.56)

0.49

1.4(0.0–2.5)

2.3(0.7–3.9)

<0.01

1.3(0–2.5)

2.8(0.7–4.6)

0.86

HAART regimen initiated

D4T-3TC-EFZ/NVP

40(14%)

242(86%)

94(62%)

154(82%)

117(38%)

110(36%)

0.62

AZT-3TC-EFZ/NVP

38(39%)

60(61%)

<0.01

57(38%)

34(18%)

<0.01

49(16%)

33(11%)

Baseline CD4 count [Median(IQR)]

123(84–186)

99(29–162)

<0.01

122(78–189)

96(14–162)

<0.01

119(77–176)

87(11–158)

<0.01

Hepatitis BSAg *

(270 tests done)

8(31%)

18(69%)

0.17

10(7%)

11(6%)

0.93

10(6%)

11(8%)

0.24

59(20%)

233(80%)

114(75%)

145(77%)

131(79%)

102(71%)